Gelafundin is an intravenous volume expander and is commonly used in acute clinical settings to manage the physiological consequences of significant fluid loss. Its role is focused on providing circulatory support and stabilization. This medicine is classified as a colloidal plasma volume substitute.

---

Supporting Circulation in Acute Crises

This solution is primarily used for volume resuscitation and is applied to help manage symptoms of absolute or relative hypovolaemia, which is a severe deficiency of circulating blood volume. It plays a role in the management of hypovolaemic shock and is considered relevant for conditions marked by significant blood loss. The core therapeutic domains include addressing fluid deficits resulting from significant haemorrhage, severe trauma, or extensive burns. The benefit supports managing effective circulating volume, contributing volume to assist with managing systemic imbalance during a critical period.

Addressing and Preventing Hemodynamic Instability

Gelafundin is applied to help address symptoms of hemodynamic instability, most notably dangerously low blood pressure (hypotension). It is also used prophylactically to help prevent a critical drop in blood pressure, such as that anticipated in a surgical setting or that which occurs during regional anaesthesia. The practical benefit supports the stabilization of the cardiovascular system and contributes to better tissue perfusion and oxygen delivery in high-risk scenarios.

---

Quick Fact: Relief for Severe Volume Deficiency Gelafundin is commonly used when symptoms are related to systemic imbalance and acute or disruptive episodes, particularly those associated with significant fluid loss.

Who can and cannot use Gelafundin?

The population eligibility for Gelafundin (succinylated gelatin) is strictly defined by regulatory documents, listing specific groups for whom the medicine is contraindicated or restricted.

---

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults (Standard population for volume replacement).

Populations for whom use is contraindicated:

• Patients with hypersensitivity to gelatin or Alpha-Gal syndrome (red meat allergy).
• Patients with existing Hypervolaemia (volume overload), Hyperhydration, or Acute congestive cardiac failure.

Age-related eligibility rules:

• Children (Pediatric): Safety and efficacy are not yet completely established. Administration is restricted and must be based on a clear benefit-risk justification.
• Older Adults (Advanced Age): Use requires caution due to the increased frequency of comorbidities, particularly cardiac or renal insufficiency.

Condition-specific eligibility rules:

• Use requires caution in patients with Renal Insufficiency or non-acute Cardiac Insufficiency.
• Pregnancy and Lactation: Use during pregnancy should be avoided unless medically required, and a decision must be made to discontinue either breastfeeding or therapy due to insufficient data.

---

Connection to the overall eligibility profile: Regulatory documents establish absolute contraindications based on immunological risk and volume status, prohibiting use in conditions like Acute congestive cardiac failure or Alpha-Gal allergy. Eligibility is otherwise constrained by mandated caution and restricted use for specific groups like pediatric patients and those with underlying organ insufficiency.

Interactions with Other Medicines and Products

Gelafundin, a plasma volume expander containing modified fluid gelatin, has documented interactions primarily related to the potential for electrolyte imbalance and influence on laboratory test results.

Interactions Affecting Electrolyte Balance:

Caution is advised when Gelafundin is co-administered with medicinal products that may cause potassium retention or sodium retention. This includes specific classes of agents, such as potassium-sparing diuretics (e.g., amiloride, spironolactone, triamterene) and Angiotensin-Converting Enzyme (ACE) inhibitors. Concomitant use with agents causing sodium retention, such as certain corticosteroids, requires caution as the combination may lead to fluid accumulation (oedema).

Concomitant Product Category	Potential Risk Profile (Regulatory Classification)
Medicines causing Potassium Retention	Use with caution; risk of increased potassium accumulation.
Medicines causing Sodium Retention	Use with caution; risk of fluid retention (oedema).

Influence on Laboratory Test Results:

The product may influence the accuracy of specific clinical-chemical tests, potentially leading to falsely high values. These affected tests include the erythrocyte sedimentation rate, the specific gravity of urine, and certain unspecific protein assays, such as the biuret method. To ensure accurate blood typing and irregular antibody testing, it is officially recommended that blood samples be drawn before the infusion of Gelafundin.

Gelafundin, a solution containing succinylated gelatin, functions as an exogenous colloid when introduced intravenously. The succinylated gelatin molecules, possessing a high molecular weight and negative charge, distribute primarily to the intravascular compartment following infusion.

This molecular structure results in a sustained high oncotic pressure within the plasma. This increase in colloidal osmotic pressure creates a gradient that facilitates the movement of interstitial water and electrolytes into the capillaries, increasing the volume of the circulating plasma. This fluid mobilization and volume retention are passive, non-receptor-mediated physical-chemical interactions governed by the Starling forces.

As a direct system-level physiological consequence of the expanded plasma volume, venous return and preload increase, which elevates cardiac stroke volume and cardiac output. This mechanical modulation of the cardiovascular system results in the restoration of intravascular pressure and tissue perfusion via an augmented circulatory volume.

How Gelafundin is Used: Official Administration Guidelines

Gelafundin (a 4% succinylated gelatin solution) is administered exclusively as an Intravenous infusion (IV). The administration is event-driven and strictly on an as-needed/on-demand basis, reflecting its use for acute fluid replacement. The dosage and infusion rate are dynamically adjusted according to the amount of fluid lost and the patient's requirement to restore a stable circulatory status.

---

Official Administration Rules

Parameter	Guideline
Standard Dosing	The dose is not fixed; typically, 500 mL to 1000 mL is administered initially. The maximum total volume is determined by the need to prevent haemodilution, ensuring the haematocrit level does not fall below critical thresholds.
Preparation	The solution may be warmed to body temperature (not exceeding 37 °C) before rapid infusion. Air must be removed from the container and infusion set when using pressure infusion.
Age-Group Rules	Pediatric: No standardized dosage exists; the solution is administered only after a careful benefit-risk assessment. Elderly: Caution is required, with close monitoring for pre-existing conditions that may lead to circulatory overload.
Procedural Conditions	The initial 20 to 30 mL of the infusion must be administered slowly. In severe, acute situations like shock, rapid pressure infusion of 500 mL may be given within 5 to 10 minutes.

---

Connection to the Overall Use Protocol

These official instructions establish a strictly short-term, acute-use protocol where the administration process is continuously monitored and tailored in real-time. The procedural steps mandate an initial slow infusion for patient observation and define permissible rapid rates and volume limits based on blood dilution to ensure administration aligns with clinical requirements.

Research Evidence: Overview of Studies for Gelafundin

Research was studied as a potential plasma volume substitute. Studies relevant to this function include randomized controlled trials (RCTs) and specialized volume kinetics research, which was applied in studies examining how circulating fluid volume changes immediately after the solution is administered. Researchers primarily monitored outcomes related to systemic or functional imbalance, such as changes in blood volume, cardiac output, and overall mean arterial pressure (MAP). The solution was evaluated alongside different fluid types in research that monitored measurements of blood volume. Follow-up durations were limited for many of these initial studies, and evidence is limited for definitive long-term outcomes.

Evidence for Use in Perioperative Fluid Management

Research was evaluated in settings that address acute fluid deficits and dangerously low blood pressure (hypotension). RCTs have explored how the solution performs when used in adult patients during surgical procedures. The outcomes measured included the frequency of low blood pressure episodes and the requirement for vasopressor support. Research examined the solution's association with biomarkers of renal tubular injury, and data are still emerging on this topic. Comparative evidence is lacking from large, definitive trials focusing strictly on long-term safety.

Evidence in Critical Care Scenarios, Including Sepsis

The evidence was evaluated in contexts involving adults experiencing conditions associated with acute or disruptive episodes, such as severe infection or septic shock. Research monitored high-level clinical outcomes such as 90-day mortality and the rate of requiring Renal Replacement Therapy (RRT). The sample sizes were modest in many of the key trials in this area, meaning the certainty remains low for definitive conclusions. Research has provided limited insight into outcomes related to systemic or functional imbalance for all patients in the complex environment of septic shock.

Common questions about Gelafundin (FAQ)

Q: What is the definition of a 'colloid' in the context of Gelafundin?

Gelafundin is classified as an intravenous colloid solution. This means it contains large molecules of gelatin that stay within the blood vessels, where they exert oncotic pressure—a physical force that draws fluid into the circulation. This action is defined as assisting in the rapid and sustained maintenance of circulating blood volume.

Q: How is Gelafundin compositionally different from normal saline or other standard IV fluids?

Gelafundin is officially classified as a colloid solution, while standard IV fluids like saline are called crystalloids. This difference is because Gelafundin contains large molecules of succinylated gelatin, a protein derivative, which are not present in crystalloid solutions. This gelatin component is what helps the fluid stay in the bloodstream for a longer period.

Q: Does Gelafundin contain any components that people with dietary restrictions should know about?

Yes, Gelafundin's active ingredient, succinylated gelatin, is derived from bovine sources (animal collagen). Furthermore, official regulatory documents state that the medicine is contraindicated (must not be used) in patients with known hypersensitivity to Alpha-Gal syndrome, which is a type of red meat allergy.

Q: What does 'contraindication' mean when it relates to the use of Gelafundin?

A contraindication is a critical safety instruction from the regulatory label stating that the medicine must never be used in patients with the listed medical conditions. For Gelafundin, these conditions include hypersensitivity to its ingredients or certain types of fluid overload (hypervolaemia).

Q: Is Gelafundin a replacement for a blood transfusion?

Gelafundin is classified as a plasma volume substitute used to restore lost volume in the circulatory system. However, regulatory documents indicate that its primary use is for volume replacement, and for significant blood losses (greater than 20%), the regulatory guidance indicates that treatment with blood or blood components is typically administered in addition to Gelafundin.

Q: Can Gelafundin be used for simple dehydration?

Official regulatory documents specify that Gelafundin is indicated for the replacement of blood and body fluid lost due to conditions like trauma, surgery, or burns, primarily to treat dangerous reductions in blood volume (hypovolaemia) and shock. It is not indicated for the treatment of simple, routine dehydration.

Q: What are the alternatives to Gelafundin, generally speaking, for its main uses?

Official label information indicates that the use of Gelafundin is appropriate in situations where standard products, known as crystalloids (such as saline), are determined to be not sufficient alone for volume replacement. This indirectly establishes crystalloid solutions as the most common primary alternative for fluid resuscitation.

Q: How long does the effect of Gelafundin typically last in the body?

Gelafundin is considered a relatively short-acting treatment. According to clinical studies cited in the product information, the volume-expanding effect of the solution lasts for approximately three to four hours after the infusion is completed.

Q: How does the body break down and eliminate Gelafundin?

According to the official product information, the major and most important route for elimination is through urinary excretion via the kidneys. Only a very minor amount of the succinylated gelatin is metabolized by the body or eliminated through other routes.

Q: Is it normal to feel a slight warmth or dizziness right after receiving Gelafundin?

Official product information indicates that side effects are generally uncommon. A mild rise in body temperature is classified as an uncommon effect, and dizziness is a reaction that has been reported, although it is classified as rare. Official administration guidelines indicate that patients are monitored closely during and after infusion.

Q: What are the symptoms of a serious adverse reaction to Gelafundin?

Serious adverse reactions, known as anaphylactic or anaphylactoid reactions, are classified as rare or very rare events. Official documentation indicates these can progress to shock and may include symptoms such as difficulty breathing, wheezing, excessive sweating, or severe systemic collapse.

Q: Does Gelafundin cause issues with kidney function according to official reports?

Official regulatory documents do not state that Gelafundin causes kidney issues in people with normal function. However, the official label requires that the solution be given with caution to individuals who have existing impaired renal function (kidney problems). This caution is mandated due to the heightened risk of fluid overload in these patients.

Q: Is it true that Gelafundin can affect blood clotting or coagulation tests?

Yes, official product information indicates that Gelafundin can influence the blood clotting process. It may cause a dilution of coagulation factors, which can lead to measurable changes in blood tests such as a prolongation of activated partial thromboplastin time (aPTT).

Q: Can Gelafundin interact with common over-the-counter pain relievers like ibuprofen?

Official interaction information advises that caution is warranted if Gelafundin is used alongside medicines that promote sodium retention. This class of interacting agents includes Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, due to a potential risk of increased fluid accumulation (oedema or swelling).

Q: Is Gelafundin commonly used in emergency room settings or just during surgery?

Gelafundin is indicated for use in acute situations to treat or prevent low blood volume (hypovolaemia) and shock. The regulatory instructions permit its administration via rapid pressure infusion when necessary, which suggests its use is intended for acute and emergency care settings, including during surgical procedures.

Q: Is Gelafundin known by any other brand names in different countries?

Yes, the active ingredient in Gelafundin, succinylated gelatin, is marketed under several different trade names across the globe. Examples of other brand names associated with this type of solution include Gelofusine and Gelaspan.

Gelafundin Storage and Disposal: Official Regulatory Requirements

Gelafundin solution for infusion requires strict adherence to documented storage and handling rules to maintain its sterile integrity. It must be stored at a temperature not exceeding 25°C and is specifically instructed not to be frozen.

Protection from light is mandatory, requiring the solution to be stored in its original outer carton until use. As a sterile product, it must be used immediately after the container is opened, and any unused solution must be discarded right away.

All medicinal product must be stored out of the sight and reach of children.

Disposal of any unused or expired solution and waste material must be carried out in accordance with local requirements for pharmaceutical waste and should not be disposed of via wastewater.